Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-116 Versus Investigator's Choice in Advanced or Metastatic Non-squamous EGFR-Wildtype NSCLC
NCT07718737Phase 3Recruiting
- Sponsor
- Multitude Therapeutics
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Countries
- 2
01
Overview
A Phase 3 trial of AMT-116 in non-small cell lung cancer (NSCLC), sponsored by Multitude Therapeutics. Started Sep 2026; status: recruiting.
02
Drugs
AMT-116
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07718737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07718737.